65 E ect of flow on longitudinal tau PET 33. Golla SS, Lubberink M, van Berckel BN, Lammertsma AA, Boellaard R. Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. EJNMMI Res. 2017;7:36. 34. Pontecorvo MJ, Devous MD, Kennedy I, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain. 2019;142:1723–1735. 35. Jack CR Jr, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain. 2018;141:1517–1528. 36. Harrison TM, La Joie R, Maass A, et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann Neurol. 2019;85:229–240. 37. Cho H, Baek MS, Lee HS, Lee JH, Ryu YH, Lyoo CH. Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease. Alzheimers Res Ther. 2020;12:114. 38. Timmers T, Ossenkoppele R, Visser D, et al. Test–retest repeatability of [18F] flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2020;40:2464–2474. 39. Carson RE, Channing MA, Blasberg RG, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24–42. 40. Baker SL, Harrison TM, Maass A, La Joie R, Jagust WJ. Effect of off-target binding on 18F-flortaucipir variability in healthy controls across the life span. J Nucl Med. 2019;60:1444–1451. 3
RkJQdWJsaXNoZXIy MjY0ODMw